Sunesis Pharmaceuticals (SNSS) Announces Quarterly Earnings, Misses Expectations By $0.01 EPS
Sunesis Pharmaceuticals (NASDAQ: SNSS) posted its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $0.32 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The company’s revenue for the quarter was up 19700.0% on a year-over-year basis.
Several analysts have also recently commented on the stock. Analysts at Credit Suisse initiated coverage on shares of Sunesis Pharmaceuticals in a research note to investors on Tuesday, January 15th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Wells Fargo initiated coverage on shares of Sunesis Pharmaceuticals in a research note to investors on Wednesday, December 19th. They set an “outperform” rating on the stock.
Sunesis Pharmaceuticals (SNSS) opened at 5.39 on Wednesday. Sunesis Pharmaceuticals (SNSS) has a 52-week low of $2.27 and a 52-week high of $6.85. The stock’s 50-day moving average is currently $5.55. The company’s market cap is $277.6 million.
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.